Metronomic Chemotherapy: A Systematic Review of the Literature and Clinical Experience

Table 5

Table showing the studies using metronomic regimens in glioblastoma multiforme (GBM). CP, Cyclophosphamide; TMZ, Temozolomide.

Author	Treatment	N	Patient type	SD	PR	ORR	TTP	PFS 6	OS
Brandes, 2006	TMZ 75 mg/ m^2 days 1-21 q28d	33	Chemonaive, refractory to RT and/or surgery	-	-	9%	-	30.3%	-
Kesari, 2007	Etoposide 35 mg/ m^2 days 1-21; CP 2 mg/kg days 22-42,; Thalidomide; Celecoxib	48	GBM and; AG	59%	11%	-	-	11 w; (GBM); 14 w; (AG)	41.5 w; (GBM); 42 w; (AG)
Balmaceda, 2008	TMZ 200 mg/ m^2; followed by; 90 mg/m2 q12h 9 times	120	GBM,; anaplastic astrocytoma,; anaplastic oligodendroglioma	-	-	-	-	4.2 m; 5.8 m; 7.7 m	8.8 m; 14.6 m; 18 m
		1:21	1:GBM-refractory to conventional TMZ,					1:17%
Perry, 2008	TMZ 50 mg/ m^2 qd	2:14	2:GBM-refractory to conventional and adjuvant TMZ	-	-	-	-	2:57%	-
		3:14	3:AG-refractory to conventional TMZ,					3:42%
Clarke, 2009	TMZ 50 mg/ m^2 qd	43	Pretreated with standard TMZ + RT	-	-	-	-	-	15.1 m
Reardon, 2009	Bevacizumab 10 mg/kg two times a week	59	GBM and grade 3 glioma	-	-	-	-	40.6%	63.1 w
	Etoposide 50 mg/ m^2 qd days 1-21 q30d							44.4%	44.4 w
Kong, 2010	TMZ 40 mg/ m^2 m^2 qd or 50 mg/ m^2qd	38	Pretreated GBM	-	-	-	-	32.5%	56.0% (6 m)
Stockhammer, 2010	TMZ 10 mg/ m^2bid; Celecoxib 200 mg	28	Pretreated GBM	-	-	-	4.2 m	43 %	-
Verhoeff, 2010	Bevacizumab 10 mg/kg q21d; TMZ 50 mg/ m^2 qd	23	High grade glioma	-	-	20%	-	17.4 %	17.1 w
Reardon, 2011	Bevacizumab 10 mg/kg q14d; With Etoposide 50 mg/ m^2 days 1-21 q 30d; or; With TMZ 50 mg/ m^2 m^2 qd	23	Bevacizumab pretreated GBM,	52%	-	-	-	4.4%	-
Omuro, 2013	TMZ 50 mg/ m^2 qd	47	Pretreated grade 3 malignant glioma and GBM	-	-	-	-	19%	7 m
Zustovich, 2013	TMZ 40 mg/ m^2qd; Sorafenib 400 mq qd	43	Pretreated GBM	-	-	-	-	26%	7.5 m